ATLANTA — Thermo Fisher Scientific Inc., the world leader in serving science, today announced validated applications for Thermo Scientific immunoassays on Ortho Clinical Diagnostics’ VITROS® Systems. There are seven new manufacturer validated applications (MVA) which include: CEDIA® Cyclosporine Plus (including separate applications for both low and high range), CEDIA® Tacrolimus and CEDIA® Mycophenolic Acid assays for monitoring immunosuppressant drugs in transplant patients, DRI® Ecstasy, DRI® Oxycodone assays screening urine samples for presence of commonly abused drugs and the QMS® Amikacin Immunoassay for measuring blood levels of this antibiotic drug. The company will showcase the validated applications at Thermo Scientific booth #1720 during Clinical Lab Expo at AACC 2011, being held July 26 – July 28, at the Georgia World Congress Center, Atlanta, Georgia.

Thermo Scientific products have a proven track record for supplying quality reagents, calibrators and controls that dates back to 1989. These homogeneous immunoassay products have been used in many major clinical laboratories and drug testing facilities around the world. In particular, the full panel of CEDIA® immunosuppressant assays plays a key role in therapeutic drug monitoring, which is an integral part in treatment programs for organ transplant recipients. As manufacturers develop new drugs, monitoring the narrow therapeutic ranges for each drug becomes more important. For example, clinical laboratories must provide accurate and dependable test results in a timely manner to the physicians, who will use to support their patient care and carefully manage dosages to avoid organ rejection caused by low levels of the immunosuppressant drugs or toxicity issues caused by excessive levels of a drug or a potentially lethal combination. While the drugs of abuse and therapeutic drug monitoring assays provide easy-to-use tools for qualitative and semi-quantitative determination of drug presence in patients Thermo Fisher is constantly innovating, delivering new assay methods, calibrators and controls that build on its history of product reliability, accuracy and ease-of-use and lot-to-lot consistency.

VITROS is a registered trademark of Ortho-Clinical Diagnostics, Inc. CEDIA is a registered trademark of Roche Diagnostics licensed for use to Microgenics, part of Thermo Fisher Scientific.

For more information about validated applications for Thermo Scientific immunoassays, please visit booth #1720 during AACC 2011. Alternatively please call 1-800-232-3342 or +1 49 (0) 851 88689 0 internationally, or visit www.thermoscientific.com.

For access to all Thermo Fisher Scientific news and product photos related to AACC 2011, please visit the online media room at http://www.thermofisher.com/AACC2011.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.